Founder and Chief Scientific Officer · NGM BIOPHARMACEUTICALS INC (NGM)

Jin-Long Chen

A named executive officer of NGM BIOPHARMACEUTICALS in every fiscal year CompBrief holds from FY2020 to FY2022. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2022

$2,506,213

Salary $550,000Stock awards $0

FY2021: $4,242,895

4th of 5 named executive officers at NGM Biopharmaceuticals by FY2022 total.

5 named officers on file for NGM BIOPHARMACEUTICALS, FY2022

Jin-Long Chen’s pay file — $29

  • 3 fiscal years of pay, line by line
  • 1 equity grant, each cited to its filing
  • NGM’s disclosed peer group of 21 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how NGM BIOPHARMACEUTICALS’s whole pay program stands against its peers

  • NGM BIOPHARMACEUTICALS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on NGM→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed March 29, 2023 (DEF 14A).

Free

Get Jin-Long Chen’s full pay file as a PDF — free

More than this page: up to 10 years of Jin-Long’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Jin-Long Chen compensation by year

NGM BIOPHARMACEUTICALS Summary Compensation Table · all 3 fiscal years held
In US dollars, as NGM BIOPHARMACEUTICALS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020FY2021FY2022
Salary$515,000$530,000$550,000
Bonus$175,000$200,000$0
Stock awards$0$0$0
Option awards$1,677,323$3,512,145$1,775,463
Non-equity incentive$0$0$180,000
Pension and deferred compensation$0$0$0
All other$750$750$750
Total$2,368,073$4,242,895$2,506,213

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: NGM BIOPHARMACEUTICALS INC DEF 14A filed March 29, 2023, accession 0001628280-23-009712, and prior-year filings.

How this page was built: the NGM BIOPHARMACEUTICALS INC filed document, accession 0001628280-23-009712. Every figure is read from that document and cited to the page and table it appears in. Filed March 29, 2023.

$2.4M
$4.2M
$2.5M
FY20
FY21
FY22
SalaryBonusNon-equity incentiveOption awardsAll other

Equity holdings

unvested awards at FY2022 year-end
TypeUnvested unitsValue at year-endExercise price
Option134,896—$15.20
Option91,146—$31.93

Per the Outstanding Equity Awards at Fiscal Year-End table in NGM BIOPHARMACEUTICALS INC's FY2022 proxy; value at the fiscal year-end close, as the company printed it.

NGM BIOPHARMACEUTICALS’s named executive officers, FY2022

as the company reported each
Named executive officerRoleFY2022 total
David WoodhouseChief Executive Officer$5,933,500
Siobhan Nolan ManginiPresident and Chief Financial Officer$3,533,780
Hsiao LieuExecutive Vice President and Chief Medical Officer$2,732,410
Jin-Long Chen · this pageFounder and Chief Scientific Officer$2,506,213
Valerie PierceSenior Vice President, General Counsel, Chief Compliance Officer and Secretary$2,102,575

Board service

NGM BIOPHARMACEUTICALS board · FY2022

How this board is paid

Company policy: NGM BIOPHARMACEUTICALS pays directors a $40,000 cash retainer and $200,000 in Options. As stated in NGM BIOPHARMACEUTICALS's FY2022 proxy.

The full NGM BIOPHARMACEUTICALS compensation record

free company brief

This page is one person within NGM BIOPHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the NGM BIOPHARMACEUTICALS proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are NGM BIOPHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Jin-Long Chen's compensation dossier · One-time report. No refunds.